Arcturus Therapeutics Holdings (ARCT) EBT: 2018-2025
Historic EBT for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to -$13.4 million.
- Arcturus Therapeutics Holdings' EBT fell 88.88% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 6.94%. This contributed to the annual value of -$80.9 million for FY2024, which is 190.23% down from last year.
- According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' EBT is -$13.4 million, which was down 46.56% from -$9.2 million recorded in Q2 2025.
- Arcturus Therapeutics Holdings' 5-year EBT high stood at $118.6 million for Q4 2022, and its period low was -$57.7 million during Q1 2021.
- Over the past 3 years, Arcturus Therapeutics Holdings' median EBT value was -$14.1 million (recorded in 2025), while the average stood at -$13.2 million.
- Per our database at Business Quant, Arcturus Therapeutics Holdings' EBT tumbled by 509.45% in 2021 and then spiked by 415.16% in 2022.
- Over the past 5 years, Arcturus Therapeutics Holdings' EBT (Quarterly) stood at -$37.6 million in 2021, then skyrocketed by 415.16% to $118.6 million in 2022, then crashed by 109.65% to -$11.4 million in 2023, then slumped by 162.20% to -$30.0 million in 2024, then slumped by 88.88% to -$13.4 million in 2025.
- Its EBT stands at -$13.4 million for Q3 2025, versus -$9.2 million for Q2 2025 and -$14.1 million for Q1 2025.